利格列汀与格列美脲对超重2型糖尿病患者肾脏生理的影响:RENALIS随机双盲试验
RENALIS双盲随机试验纳入46例无肾损害的超重2型糖尿病患者,在二甲双胍基础上分别加用利格列汀5 mg或格列美脲1 mg治疗8周。两组HbA1c降幅相似(利格列汀-0.45±0.09% vs 格列美脲-0.65±0.10%,P=0.101)。利格列汀对GFR、ERPF及肾损伤标志物无影响,仅增加钠和钾的分数排泄,且钠排泄变化与SDF-1α相关(R=0.660)。
要点
- 利格列汀与格列美脲降糖效果相似,对 fasting 肾血流动力学均无显著影响。
- 利格列汀可促进轻度利钠,可能由SDF-1α介导,作用位点可能在致密斑远端。
- 利格列汀不影响锂的分数排泄,提示其利钠作用不涉及近端小管。
核心结论
- 在二甲双胍治疗的超重2型糖尿病患者中,利格列汀对比格列美脲不影响空腹肾血流动力学。
- DPP-4抑制可促进轻度利钠,可能由SDF-1α介导,且作用位点可能在致密斑远端。
研究设计与样本
- 双盲随机试验,46例无肾损害的超重2型糖尿病患者,每日一次利格列汀5 mg或格列美脲1 mg治疗8周。
- 采用菊粉和對氨基马尿酸清除率测定空腹GFR和ERPF,并检测分数排泄、尿损伤标志物及循环DPP-4底物。
主要发现
- 8周后HbA1c降幅利格列汀为-0.45±0.09%,格列美脲为-0.65±0.10%,两组差异无统计学意义(P=0.101)。
- 利格列汀对比格列美脲未影响GFR、ERPF、估算的肾内血流动力学或损伤标志物。
- 仅利格列汀增加钠和钾的分数排泄,不影响锂的分数排泄。
- 利格列汀引起的钠分数排泄变化与SDF-1α相关(R=0.660),与其他DPP-4底物无关。
临床怎么用
- 对于无肾损害的超重2型糖尿病患者,利格列汀对空腹肾血流动力学无不良影响,可考虑作为二甲双胍add-on选项。
- 利格列汀的轻度利钠作用可能有助于容量管理,但需结合临床情况评估。
局限性
- 样本量较小(46例),研究周期仅8周。
- 仅评估空腹肾血流动力学,未涉及餐后或长期肾脏结局。
- 研究对象为无肾损害的超重患者,结果不能外推至肾功能不全人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare effects of the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin with those of a sulfonylurea on renal physiology in metformin-treated patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks. Fasting glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined by inulin and para-aminohippuric acid clearances. Fractional excretions, urinary damage markers, and circulating DPP-4 substrates (among others, glucagon-like peptide 1 and stromal cell-derived factor-1α [SDF-1α]) were measured. RESULTS: HbA1c reductions were similar with linagliptin (-0.45 ± 0.09%) and glimepiride (-0.65 ± 0.10%) after 8 weeks (P = 0.101). Linagliptin versus glimepiride did not affect GFR, ERPF, estimated intrarenal hemodynamics, or damage markers. Only linagliptin increased fractional excretion (FE) of sodium (FENa) and potassium, without affecting FE of lithium. Linagliptin-induced change in FENa correlated with SDF-1α (R = 0.660) but not with other DPP-4 substrates. CONCLUSIONS: Linagliptin does not affect fasting renal hemodynamics compared with glimepiride in T2DM patients. DPP-4 inhibition promotes modest natriuresis, possibly mediated by SDF-1α, likely distal to the macula densa.
引用
- Muskiet MHA, Tonneijck L, Smits MM, et al. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. Diabetes Care. 2020. PMID: 32900785. doi:10.2337/dc20-0902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。